Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | LPL | P06858 | 5/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1428092 | 0.98 | HRH3 (0.55) | HRH3LPLLIPGHRH4ALDH1A1 | |
| SCHEMBL1354581 | 0.98 | LPL (0.54) | HRH3LPLLIPGHRH4ALDH1A1 | |
| SCHEMBL3319981 | 0.95 | LPL (0.54) | HRH3LPLLIPGHRH4ALDH1A1 | |
| SCHEMBL16121847 | 0.87 | CHKA (0.60) | LPLLIPGKDM4E | |
| SCHEMBL1427702 | 0.86 | LPL (0.51) | HRH3LPLLIPGF11 | |
| SCHEMBL5254853 | 0.86 | LPL (0.55) | LPLLIPGALDH1A1KDM4EF11 | |
| SCHEMBL146568 | 0.86 | HRH3 (0.56) | HRH3LPLLIPGALDH1A1F11 | |
| SCHEMBL429722 | 0.86 | LMNA (0.53) | LPLLIPGALDH1A1KDM4EF11 | |
| SCHEMBL18579941 | 0.85 | L3MBTL3 (0.52) | HRH3LPLLIPGALDH1A1F11 | |
| SCHEMBL3264618 | 0.85 | POLB (0.55) | LPLLIPGALDH1A1KDM4EF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4548919-A2 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | UCL Business Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129065-A1 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | UCL BUSINESS LTD (GB) | 2025-04-24 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| EP-3969451-B1 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | UCL BUSINESS LTD (GB) | 2025-02-12 | — | — | EP | disclosed |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2024008909-A1 | INHIBITORS OF CORONAVIRUS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
| US-20230212166-A1 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | UCL BUSINESS LTD (GB) | 2023-07-06 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A5 | HRH3 63/4885LPL 4800/4885LIPG 4830/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | HRH3 488/4885LPL 4706/4885LIPG 4135/4885 |
| US-20250129065-A1 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | NDC1, DDB1, DDX21 | HRH3 3300/4885LPL 4481/4885LIPG 4565/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | HRH3 2320/4885LPL 3069/4885LIPG 3164/4885 |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK2, CLK1, CLK3 | HRH3 2345/4885LPL 4658/4885LIPG 4105/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | HRH3 2345/4885LPL 4658/4885LIPG 4105/4885 |
| US-20230212166-A1 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | NDC1, DDB1, DDX21 | HRH3 3300/4885LPL 4481/4885LIPG 4565/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | HRH3 2320/4885LPL 3069/4885LIPG 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.